Richard Johnson

Younger people with severe COVID-19 complications have a high frequency of obesity, and elevated uric acid may play a role in their increased risk.

"younger people, especially the younger people who have serious COVID-related complications, there's a high frequency of obesity in that group. And we think that one of the thoughts is that the uric acid may be playing a role in why they're at increased risk." (said at 0:00:00)

The speaker accurately states two related observations: obesity is a prominent risk factor for severe COVID-19 outcomes in younger demographics, and researchers have hypothesized that elevated uric acid (hyperuricemia)—which is strongly linked to obesity and metabolic syndrome—may contribute to the increased risk of severe COVID-19 complications and organ damage. Observational cohort data in hospitalized COVID-19 patients show that higher serum uric acid levels are independently associated with acute kidney injury, major adverse kidney events, and in-hospital mortality in a dose-dependent manner. Because the available evidence is observational and the causal role of uric acid remains hypothetical, the overall certainty of evidence is low.

• supports: Prevalence and Outcomes Associated with Hyperuricemia in Hospitalized Patients with COVID-… (American journal of nephrology 2022) · cited 21x in the literature

  "In patients admitted to the hospital for COVID-19, higher serum UA levels were independently associated with AKI, MAKE, and in-hospital mortality in a dose-dependent manner. In addition, hyperuricemia was associated with higher procalcitonin and troponin I levels." (abstract, conclusions, passage verified)

  pubmedfull study (doi)

Only a small amount of dietary fructose enters the brain, but consumption of sugar, salt, and high-glycemic carbohydrates stimulates endogenous fructose production in the brain.

"when you eat fructose, only a small amount of fructose gets to the brain. So you would think that the brain would be safe from the effects of fructose to some extent. But what happens is the brain can actually make fructose. And when you eat sugar, we don't totally know the mechanism, but it seems that that stimulates fructose production in the brain. So sugar and salt and high-glycemic carbs all seem to drive fructose production in the brain." (said at 0:04:43)

Human and animal studies confirm that only minimal dietary fructose crosses the blood-brain barrier under physiological conditions, but the brain produces fructose endogenously from glucose via the polyol pathway (aldose reductase and sorbitol dehydrogenase). In humans undergoing hyperglycemic clamp experiments, intracerebral fructose increased significantly in response to elevated cerebral glucose. Mechanistic studies and reviews also demonstrate that high-glycemic loads and hyperosmolar stimuli (such as high salt) activate aldose reductase, driving endogenous fructose production in tissues including the hypothalamus.

• supports: The human brain produces fructose from glucose. (JCI insight 2017) · cited 95x in the literature

  "To determine whether fructose can be endogenously generated from glucose via the polyol pathway (glucose → sorbitol → fructose) in human brain, 8 healthy subjects... underwent 1 H magnetic resonance spectroscopy scanning to measure intracerebral glucose and fructose levels during a 4-hour hyperglycemic clamp (plasma glucose, 220 mg/dl)... Intracerebral fructose levels also rose over time, differing from baseline at 30 to 230 minutes. The changes in intracerebral fructose were related to changes in intracerebral glucose but not to plasma fructose levels. Our findings suggest that the polyol pathway contributes to endogenous CNS production of fructose" (abstract, results and conclusions)

  pubmedfull study (doi)
• supports: Endogenous fructose production: what do we know and how relevant is it? (Current opinion in clinical nutrition and metabolic care 2019) · cited 39x in the literature

  "Over the recent years, the activation of the polyol pathway and endogenous fructose production has been observed in multiple tissues including the liver, renal cortex, and hypothalamic areas of the brain. The activation occurs during the development and progression of metabolic syndrome and kidney disease and results from different stimuli including osmotic effects, diabetes, and ischemia." (abstract, results, passage verified)

  pubmedfull study (doi)

The enzyme AMP deaminase is elevated in the brains of patients with Alzheimer's disease.

"there's an enzyme that's turned on when fructose is metabolized, and we think it's the key enzyme that drives this survival switch, this energy shift, and it's called AMP deaminase. But that enzyme is elevated—AMP deaminase is high in the brains of patients with Alzheimer's." (said at 0:12:00)

Postmortem human brain tissue studies confirm that AMP deaminase enzymatic activity, protein, and mRNA expression are elevated in patients with Alzheimer's disease compared to age-matched controls (showing 1.6- to 2.4-fold increases across multiple examined brain regions). Because this evidence comes from small observational postmortem studies, certainty is rated as low.

• supports: Elevated adenosine monophosphate deaminase activity in Alzheimer's disease brain. (Neurobiology of aging 1998) · cited 33x in the literature

  "Compared to control brain, Alzheimer's disease brain AMP deaminase activity is 1.6- to 2.4-fold greater in the regions examined--the cerebellum, occipital cortex, and temporal cortex. Similar increases in AMP deaminase protein and mRNA levels are observed in Alzheimer's disease brain." (abstract, results, passage verified)

  pubmedfull study (doi)

Gout patients can develop uric acid crystal deposits in their blood vessels and kidneys in addition to their joints.

"Patients with gout have these crystals in their joints, but we're now discovering that they can get crystals in their blood vessels and in their kidneys and other sites." (said at 0:20:40)

Modern advanced imaging techniques—specifically dual-energy computed tomography (DECT)—as well as histopathological and autopsy studies have confirmed that patients with gout can develop monosodium urate (MSU) crystal deposits in extra-articular tissues beyond the joints. This includes the vasculature (e.g., coronary arteries, aorta, and peripheral vessels), the kidneys (interstitial MSU deposition and uric acid nephrolithiasis), and other anatomical sites (e.g., the spine, eyes, and skin).

• supports: Systemic Urate Deposition: An Unrecognized Complication of Gout? (Journal of clinical medicine 2020) · cited 66x in the literature

  "Recent diagnostic testing, such as dual energy computed tomography (DECT), has led to the recognition that urate deposits are not uncommon in other tissues including the vasculature. To understand the potential risks for untreated gout, we reviewed the literature on extra-articular urate deposition documented by autopsy, histopathology, surgery, and radiology, including the heart, blood vessels, kidney, spine, eye, skin, and gastrointestinal system." (abstract, passage verified)

  pubmedfull study (doi)
• supports: What Has Dual Energy CT Taught Us About Gout? (Current rheumatology reports 2021) · cited 18x in the literature

  "DECT also has the ability to detect vascular MSU deposition. This correlates with high coronary calcium scores and elevated Framingham cardiovascular risk. DECT continues to aid our understanding of articular and extra-articular MSU deposition, including the role of vascular MSU deposition on cardiovascular health." (abstract, passage verified)

  pubmedfull study (doi)

Elevated serum uric acid levels are associated with an increased risk of stroke.

"There are some studies in patients with stroke where it's been shown that if you have a high uric acid, you're at an increased risk for stroke, that's for sure." (said at 0:21:00)

Multiple systematic reviews and meta-analyses of prospective cohort studies confirm that elevated serum uric acid (SUA) levels are significantly associated with an increased risk of stroke, including both ischemic and hemorrhagic stroke.

• supports: Serum uric acid and risk of stroke: a dose-response meta-analysis. (Journal of clinical biochemistry and nutrition 2021) · cited 21x in the literature

  "Twenty-one cohort studies involving 818,098 participants were included. The pooled relative risk for the high-vs-low categories was 1.22 (95% CI: 1.15-1.30). In addition, there was a non-linear dose-response relationship between uric acid and stroke risk." (abstract, results, passage verified)

  pubmedfull study (doi)
• supports: The Relationship Between Elevated Serum Uric Acid and Risk of Stroke in Adult: An Updated … (Frontiers in neurology 2021) · cited 36x in the literature

  "Overall analyses results showed a significant association between a 1 mg/dl increase in high levels of SUA and the risk of total stroke (HR = 1.13; 95% CI: 1.09-1.18; P < 0.001), ischemic stroke (HR = 1.15; 95% CI: 1.10-1.21; P < 0.001), and hemorrhagic stroke (HR = 1.07; 95% CI: 1.00 to 1.15; P = 0.046)." (abstract, results)

  pubmedfull study (doi)

Extracellular uric acid reacts with certain radicals like peroxynitrite to remove them, but transiently generates peroxynitrite-like radicals in the process.

"uric acid does block some forms of oxidative stress, but it also can generate oxidative stress even extracellularly because when it reacts with certain radicals, it produces new radicals. And this is a problem of oxidants and antioxidants, and some of them can become a radical of themselves when they bind an oxidant. So they remove peroxynitrite, but they produce a peroxynitrite-like radical at least transiently." (said at 0:21:12)

The claim accurately reflects established biochemical findings regarding uric acid's dual antioxidant/pro-oxidant role. In vitro chemical studies demonstrate that uric acid scavenges peroxynitrite, but the reaction generates urate-derived free radicals (specifically identified as aminocarbonyl radicals and urate radicals), which can transiently propagate lipid peroxidation and other oxidative processes extracellularly.

• supports: Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and ampl… (Archives of biochemistry and biophysics 1999) · cited 276x in the literature

  "Our results demonstrated that urate reacts with peroxynitrite with an apparent second order rate constant of 4.8 x 10(2) M(-1). s(-1) in a complex process, which is accompanied by oxygen consumption and formation of allantoin, alloxan, and urate-derived radicals. The main radical was identified as the aminocarbonyl radical by the electrospray mass spectra of its 5, 5-dimethyl-l-pyrroline N-oxide adduct... Production of the aminocarbonyl radical, however, may propagate oxidative reactions. We demonstrated that this radical is likely to be the species responsible for the effects of urate in amplifying peroxynitrite-mediated oxidation of liposomes and LDL" (abstract, results and conclusions, passage verified)

  pubmedfull study (doi)

Clinical studies in Spain have investigated intravenous uric acid infusion acutely in stroke patients and suggested potential acute benefits.

"if you have a stroke, there's a group in—I believe the guy is in Spain, but he has done some studies where they've infused uric acid acutely in stroke, and they actually think that it might provide a little bit of benefit acutely." (said at 0:22:00)

The speaker's claim is supported by the URICO-ICTUS trial and its subsequent analyses, led by Dr. Angel Chamorro's group in Spain. In this randomized, double-blind, placebo-controlled phase 2b/3 trial, patients with acute ischemic stroke received an intravenous infusion of 1000 mg of uric acid (or placebo) during alteplase administration (PMID: 24703208). Although the primary outcome (excellent functional outcome at 90 days) did not reach statistical significance in the overall cohort (39% vs 33%, p=0.099), subsequent analyses suggested potential acute benefits, such as a reduction in early ischemic worsening (PMID: 27758945) and improved outcomes in patients who also underwent mechanical thrombectomy (PMID: 28345429).

• supports: Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised… (The Lancet. Neurology 2014) · cited 280x in the literature

  "URICO-ICTUS was a randomised, double-blind, placebo-controlled, phase 2b/3 trial that recruited patients with acute ischaemic stroke admitted to ten Spanish stroke centres. Patients were included if they were aged 18 years or older, had received alteplase within 4·5 h of symptom onset... Patients were randomly allocated (1:1) to receive uric acid 1000 mg or placebo (both infused intravenously in 90 min during the infusion of alteplase)..." (abstract, methods, passage verified)

  pubmedfull study (doi)
• supports: Uric Acid Therapy Prevents Early Ischemic Stroke Progression: A Tertiary Analysis of the U… (Stroke 2016) · cited 81x in the literature

  "UA therapy may prevent EIW after acute stroke in thrombolysed patients. Optimal access of UA to its molecular targets through appropriate collaterals may modify the magnitude of the neuroprotective effect." (abstract, conclusions, passage verified)

  pubmedfull study (doi)
• supports: Uric acid therapy improves the outcomes of stroke patients treated with intravenous tissue… (International journal of stroke : official journal of the International Stroke Society 2017) · cited 76x in the literature

  "Uric acid therapy was safe and improved stroke outcomes in stroke patients receiving intravenous thrombolysis followed by thrombectomy." (abstract, conclusions, passage verified)

  pubmedfull study (doi)

Mitochondrial oxidative stress induced by uric acid inhibits aconitase in the Krebs cycle, stimulating citrate accumulation, fat production, and insulin resistance while blocking beta-oxidation of fatty acids.

"when you create oxidative stress inside the cell, and especially in the mitochondria, the place where ATP is made, what the oxidative stress does is it works on the Krebs cycle to inhibit it. And it inhibits a specific enzyme called aconitase, and this enzyme is involved in the ATP production that's produced through the Krebs cycle. When it does that, it shifts—it causes a stimulation of citrate, which actually activates a pathway that leads to fat production. And so what happens is that oxidative stress is actually important in the stimulation of fat synthesis. So it stimulates the cell to produce fat, it also is involved in the insulin resistance that develops, and it also blocks the burning of fatty acids, what we call the beta fatty acid cycle." (said at 0:23:43)

The speaker's description matches the mechanism reported in published laboratory studies (mostly in cell cultures and animal models). Specifically, Lanaspa et al. (2012, PMID: 23035112) demonstrated that intracellular uric acid generates mitochondrial oxidative stress, which inhibits mitochondrial aconitase in the Krebs cycle. This causes accumulation and exportation of citrate to the cytosol, which activates lipogenic enzymes (such as ATP citrate lyase) leading to de novo fatty acid synthesis and insulin resistance/steatosis. Furthermore, studies on endothelial cells (Sanchez-Lozada et al., 2012, PMID: 23235493) confirmed uric acid-induced aconitase-2 activity reduction alongside decreased expression of enoyl-CoA hydratase-1 (an enzyme involved in beta-oxidation of fatty acids). Because the evidence for this specific biochemical sequence comes from preclinical cell culture and animal models, the grade of certainty is low.

• supports: Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: poten… (The Journal of biological chemistry 2012) · cited 713x in the literature

  "Mitochondrial oxidative stress results in the inhibition of aconitase in the Krebs cycle, resulting in the accumulation of citrate and the stimulation of ATP citrate lyase and fatty-acid synthase leading to de novo lipogeneis." (abstract, results, passage verified)

  pubmedfull study (doi)
• supports: Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and… (Nephron. Experimental nephrology 2012) · cited 354x in the literature

  "UA also decreased aconitase-2 activity and lowered enoyl CoA hydratase-1 expression." (abstract, results, passage verified)

  pubmedfull study (doi)

Initial fructose metabolism consumes intracellular ATP, causing intracellular phosphate and ATP levels to fall while suppressing AMP-activated protein kinase (AMPK) activation.

"initially when the fructose is first being metabolized, it burns a lot of ATP. So the ATP levels start to fall, and then when that intracellular phosphate level falls, then it stimulates the sweeping away of the AMP, which is normally regenerated to ATP. So it consumes the ATP, and then it prevents it from being regenerated because the AMP is swept away, and it also blocks an enzyme that helps produce the ATP called AMP-activated protein kinase." (said at 0:27:45)

The speaker accurately outlines the biochemical mechanism of early fructose metabolism. Rapid phosphorylation of fructose by fructokinase (ketohexokinase) consumes ATP and depletes intracellular phosphate and ATP pools. The decline in intracellular phosphate relieves allosteric inhibition of AMP deaminase, driving generated AMP into the purine degradation pathway (leading to uric acid synthesis) rather than allowing its recycling back into ATP or sustained canonical activation of AMP-activated protein kinase (AMPK).

• supports: Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: poten… (The Journal of biological chemistry 2012) · cited 713x in the literature

  "Here, we show that fructose also stimulates triglyceride synthesis via a purine-degrading pathway that is triggered from the rapid phosphorylation of fructose by fructokinase. Generated AMP enters into the purine degradation pathway through the activation of AMP deaminase resulting in uric acid production and the generation of mitochondrial oxidants." (abstract, results, passage verified)

  pubmedfull study (doi)
• supports: Cerebral Fructose Metabolism as a Potential Mechanism Driving Alzheimer's Disease. (Frontiers in aging neuroscience 2020) · cited 70x in the literature

  "Fructose is unique among nutrients because it activates a survival pathway to protect animals from starvation by lowering energy in cells in association with adenosine monophosphate degradation to uric acid." (abstract, passage verified)

  pubmedfull study (doi)

Sugar, high-fructose corn syrup, and soft drinks are major risk factors for non-alcoholic fatty liver disease (NAFLD).

"But sugar and high-fructose corn syrup and soft drinks are a major risk factor for fatty liver, non-alcoholic fatty liver disease." (said at 0:30:35)

The claim is supported by extensive evidence from both observational meta-analyses and controlled clinical trials. A dose-response meta-analysis of observational studies (PMID: 31234281) demonstrated that sugar-sweetened beverage consumption is associated with a 39% overall increase in the odds of NAFLD in a dose-dependent manner (reaching a 53% increase with ≥7 cups/week). Furthermore, a meta-analysis of 51 controlled feeding trials (PMID: 35889803) showed with high GRADE certainty that adding excess calories from fructose-containing sugar-sweetened beverages directly increases intrahepatocellular lipid (liver fat) accumulation.

• supports: Consumption of Sugar-Sweetened Beverages Has a Dose-Dependent Effect on the Risk of Non-Al… (International journal of environmental research and public health 2019) · cited 114x in the literature

  "Twelve studies recruiting a total of 35,705 participants were included. The results showed that the consumption of SSBs was associated with 1.39-fold increased odds of NAFLD (95% CI: 1.29-1.50, p < 0.00001). The risk of NAFLD rose with an increased consumption of SSBs, while the consumptions of low doses (<1 cup/week), middle doses (1-6 cups/week) and high doses (≥7 cups/week) of SSBs increased the relative risk of NAFLD by 14%, 26% and 53%, respectively" (abstract, results)

  pubmedfull study (doi)
• supports: Important Food Sources of Fructose-Containing Sugars and Non-Alcoholic Fatty Liver Disease… (Nutrients 2022) · cited 58x in the literature

  "There was evidence of influence by food source with SSBs increasing IHCL and ALT in addition trials and mixed sources (with SSBs) decreasing AST in subtraction trials. The certainty of evidence was high for the effect on IHCL and moderate for the effect on ALT for SSBs in addition trials" (abstract, results, passage verified)

  pubmedfull study (doi)

Non-alcoholic fatty liver disease and alcoholic liver disease share biochemical abnormalities including low AMP, high oxidative stress, and elevated uric acid.

"And the two have some of the same biochemical problems, like AMP is low in both, oxidative stress is high in both, uric acid is high in both, and so forth." (said at 0:31:55)

Published human, animal, and mechanistic literature confirms that non-alcoholic fatty liver disease (NAFLD/MASLD) and alcohol-associated liver disease (ALD) share key biochemical pathways. Both fructose/nutrient overload in NAFLD and ethanol metabolism in ALD drive nucleotide turnover (via AMP deaminase activation leading to transient depletion of cellular ATP/AMP and rapid purine degradation), elevated uric acid generation, and increased oxidative stress and reactive oxygen species.

• supports: Elevated Fructose and Uric Acid Through Aldose Reductase Contribute to Experimental and Hu… (Hepatology (Baltimore, Md.) 2020) · cited 50x in the literature

  "We demonstrated in liver specimens from patients with alcoholic hepatitis, the AR up-regulation and elevated AR metabolites (sorbitol, fructose, and uric acid), which correlated significantly with (1) increased lipid peroxidation byproducts and endoplasmic reticulum (ER) stress, (2) decreased protective ER chaperones, and (3) greater cell death and liver injury." (abstract, results, passage verified)

  pubmedfull study (doi)
• supports: Fructose and the Liver. (International journal of molecular sciences 2021) · cited 155x in the literature

  "Fructose overconsumption may result in insulin resistance, oxidative stress, inflammation, elevated uric acid levels, increased blood pressure, and increased triglyceride concentrations in both the blood and liver. Non-alcoholic fatty liver disease (NAFLD) is a term widely used to describe excessive fatty infiltration in the liver in the absence of alcohol" (abstract, passage verified)

  pubmedfull study (doi)

Co-administering fructose or sugar with alcohol accelerates alcohol metabolism and increases voluntary alcohol intake in animal models.

"And it's also known that when you give alcohol and sugar together, that the sugar or fructose makes the alcohol more powerful, it accelerates alcohol metabolism, and the two work together. And like if we give an animal alcohol and we give it sugar, it will increase its alcohol intake, and not only that, it will—they will get much more dramatic liver disease." (said at 0:32:55)

Co-administration of fructose or carbohydrate solutions with ethanol accelerates alcohol metabolism and clearance from the bloodstream (often referred to as the 'fructose effect'), demonstrated in both animal models and clinical human trials.

• supports: Fructose-induced increase in ethanol metabolism and the risk of Syndrome X in man. (Comptes rendus biologies 2009) · cited 9x in the literature

  "Results show that the administered dose of fructose significantly (P<0.05) reduced the duration of alcohol intoxication by 30.7%, and accelerated the elimination (metabolism) of alcohol from bloodstream by 44.7% (P<0.05)." (abstract, results)

  pubmedfull study (doi)
• supports: The fructose-dependent acceleration of ethanol metabolism. (Biochemical pharmacology 2021) · cited 9x in the literature

  "Ethanol oxidation by rat hepatocytes was increased by more than 50% with the addition of fructose. The stimulation was accompanied by increased glucose, glycerol, lactate and sorbitol production. A similar effect was observed with sorbose, while tagatose had no effect. The same pattern was observed in the in vivo experiments." (abstract, results, passage verified)

  pubmedfull study (doi)
• supports: Dietary carbohydrate accelerates ethanol elimination, but does not alter hepatic alcohol d… (Alcoholism, clinical and experimental research 1993) · cited 16x in the literature

  "In this study, adult female rats, fed chow diets supplemented with fructose or glucose in their drinking water for 10 days demonstrated significantly greater ethanol elimination rates (4.85 +/- 0.28 and 4.92 +/- 1.56 microM ethanol/min/g liver, respectively) than rats receiving water (3.65 +/- 0.29)." (abstract, results, passage verified)

  pubmedfull study (doi)

Alcohol consumption activates an enzyme that converts glucose to fructose, causing endogenous fructose synthesis in the liver.

"when you drink alcohol, the alcohol activates an enzyme to make fructose in the body. It's not the alcohol becoming fructose. The alcohol is alcohol, but the alcohol affects an enzyme that's normally not active and it gets turned on by alcohol, and this enzyme converts glucose to fructose and you start making fructose." (said at 0:33:25)

The speaker accurately describes the activation of the polyol pathway by alcohol. Research in human liver specimens and animal models shows that ethanol consumption upregulates aldose reductase (AR), the rate-limiting enzyme of the polyol pathway that converts glucose to sorbitol (which is subsequently converted to fructose). This pathway leads to endogenous fructose generation in the liver and contributes to alcohol-induced metabolic dysfunction and liver injury.

• supports: Elevated Fructose and Uric Acid Through Aldose Reductase Contribute to Experimental and Hu… (Hepatology (Baltimore, Md.) 2020) · cited 50x in the literature

  "We demonstrated in liver specimens from patients with alcoholic hepatitis, the AR up-regulation and elevated AR metabolites (sorbitol, fructose, and uric acid), which correlated significantly with (1) increased lipid peroxidation byproducts and endoplasmic reticulum (ER) stress, (2) decreased protective ER chaperones, and (3) greater cell death and liver injury." (abstract, results, passage verified)

  pubmedfull study (doi)
• supports: Identification of a common ketohexokinase-dependent link driving alcohol intake and alcoho… (Nature metabolism 2025) · cited 4x in the literature

  "Ethanol consumption increased portal vein osmolality and activated the polyol pathway in the liver and intestine, leading to fructose production metabolized by KHK-A/C." (abstract, results, passage verified)

  pubmedfull study (doi)

A human study showed that aldose reductase is activated and fructose is present in the liver of individuals drinking alcohol.

"And so this group from Kentucky actually did a beautiful study in humans and showed that this enzyme is turned on in the liver of people drinking alcohol and that there's fructose in the liver of people drinking alcohol." (said at 0:34:26)

A 2020 study by researchers investigating alcohol-associated liver disease examined human liver specimens from patients with alcoholic hepatitis (alongside experimental animal models) and demonstrated significant upregulation of aldose reductase (AR) as well as elevated levels of its downstream metabolites, including sorbitol and fructose, in the liver.

• supports: Elevated Fructose and Uric Acid Through Aldose Reductase Contribute to Experimental and Hu… (Hepatology (Baltimore, Md.) 2020) · cited 50x in the literature

  "We demonstrated in liver specimens from patients with alcoholic hepatitis, the AR up-regulation and elevated AR metabolites (sorbitol, fructose, and uric acid), which correlated significantly with (1) increased lipid peroxidation byproducts and endoplasmic reticulum (ER) stress, (2) decreased protective ER chaperones, and (3) greater cell death and liver injury." (abstract, results, passage verified)

  pubmedfull study (doi)

In animal models, blocking fructose metabolism or blocking aldose reductase prevents alcohol-induced fatty liver disease.

"when we blocked fructose metabolism, we could block the fatty liver that was induced by alcohol. ... There was a group in China that blocked the enzyme that converts glucose to fructose, and they could block alcoholic liver disease that way in animals too." (said at 0:34:56)

The speaker's statement is supported by animal studies. In mouse models of alcohol-associated liver disease (ALD), genetic knockout of ketohexokinase (KHK-A/C, which blocks fructose metabolism) protects mice against alcohol-induced hepatic steatosis, inflammation, and fibrosis. Similarly, genetic deletion or pharmacological inhibition of aldose reductase (the rate-limiting enzyme of the polyol pathway converting glucose to sorbitol/fructose) prevents alcohol-induced hepatic steatosis and liver injury in rodents. Because the evidence for this specific claim is derived entirely from animal and cell culture models, certainty is rated as very low.

• supports: Inhibition of aldose reductase ameliorates alcoholic liver disease by activating AMPK and … (Molecular medicine reports 2017) · cited 21x in the literature

  "In addition to the elevation in AR, hepatic steatosis was observed in ethanol diet-fed mice, and this ethanol-induced steatosis was significantly attenuated by inhibiting AR activity with a specific inhibitor, zopolrestat." (abstract, results)

  pubmedfull study (doi)
• supports: Elevated Fructose and Uric Acid Through Aldose Reductase Contribute to Experimental and Hu… (Hepatology (Baltimore, Md.) 2020) · cited 50x in the literature

  "Furthermore, we established a causal role for AR in ALD by showing that the genetic deficiency of AR (knockout mice) prevented alcohol-induced increase in harmful AR metabolites, toxic aldehydes, steatosis, ER stress, apoptosis, and liver injury. Finally, we demonstrated the therapeutic potential of pharmacological AR inhibition against alcohol-induced hepatic injury in experimental ALD." (abstract, results, passage verified)

  pubmedfull study (doi)
• supports: Identification of a common ketohexokinase-dependent link driving alcohol intake and alcoho… (Nature metabolism 2025) · cited 4x in the literature

  "Under ethanol pair-matched conditions, global and liver-specific KHK-A/C knockout mice were protected from ALD, with marked reductions in hepatic steatosis, inflammation and fibrosis." (abstract, results, passage verified)

  pubmedfull study (doi)

The polyol pathway via aldose reductase is the only enzymatic pathway by which the body synthesizes endogenous fructose.

"and there's only one way the body makes fructose, only one, and it's through this enzyme called aldose reductase, or what I call the polyol pathway." (said at 0:38:04)

The speaker's statement is biochemically accurate. In mammalian biochemistry, the polyol pathway (in which aldose reductase converts glucose to sorbitol, followed by sorbitol dehydrogenase converting sorbitol to fructose) is the only known enzymatic pathway for the endogenous synthesis of fructose from glucose.

• supports: Endogenous fructose production and metabolism in the liver contributes to the development … (Nature communications 2013) · cited 248x in the literature

  "High serum glucose concentrations are known to induce the polyol pathway and increase fructose generation in the liver." (abstract, passage verified)

  pubmedfull study (doi)
• supports: Aldose reductase, fructose and fat production in the liver. (The Biochemical journal 2025) · cited 8x in the literature

  "However, there has also been the recognition that fructose can be produced directly from intracellular glucose via the evolutionarily conserved polyol pathway whose access is governed by aldose reductase (AR)." (abstract, passage verified)

  pubmedfull study (doi)

Reduced blood flow during a heart attack stimulates local fructose synthesis in the heart via aldose reductase.

"So it gets turned on, for example, like if you have a heart attack, when the blood flow is low to the heart, that will stimulate local production of fructose in the heart." (said at 0:38:35)

The speaker accurately describes the activation of the polyol pathway during myocardial ischemia. Under conditions of reduced blood flow (such as during a myocardial infarction or cardiac ischemia), flux through aldose reductase is stimulated, initiating the two-step polyol pathway where glucose is reduced to sorbitol by aldose reductase and subsequently oxidized to fructose by sorbitol dehydrogenase. Evidence for this local cardiac pathway activation and its contribution to ischemic injury comes primarily from animal models and preclinical tissue studies.

• supports: Aldose reductase and cardiovascular diseases, creating human-like diabetic complications i… (Circulation research 2010) · cited 163x in the literature

  "Under diabetic conditions AR converts glucose into sorbitol, which is then converted to fructose. This article reviews the biology and pathobiology of AR actions. AR expression varies considerably among species. In humans and rats, the higher level of AR expression is associated with toxicity. Flux via AR is increased by ischemia and its inhibition during ischemia reperfusion reduces injury." (abstract, background and results, passage verified)

  pubmedfull study (doi)
• supports: Cardiomyocyte aldose reductase causes heart failure and impairs recovery from ischemia. (PloS one 2012) · cited 50x in the literature

  "Aldose reductase (AR), an enzyme mediating the first step in the polyol pathway of glucose metabolism, is associated with complications of diabetes mellitus and increased cardiac ischemic injury." (abstract, introduction, passage verified)

  pubmedfull study (doi)

Elevated uric acid levels directly stimulate and activate aldose reductase, driving further endogenous fructose production.

"When uric acid goes up, it activates aldose reductase. So uric acid is one of the—in fact, we have thought that although uric acid causes this oxidative stress and all these things that are bad, we have considered the possibility that this feedback loop to stimulate aldose reductase may be one of the stronger mechanisms by which uric acid is causing its problems." (said at 0:39:37)

Preclinical in vitro and animal studies demonstrate that uric acid upregulates aldose reductase expression (via oxidative stress and NFAT5 activation), leading to increased endogenous fructose synthesis and establishing a positive feedback loop. Evidence to date is limited to cell culture and rodent models, so certainty is very low.

• supports: Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fa… (The Journal of biological chemistry 2019) · cited 126x in the literature

  "Uric acid dose-dependently stimulated aldose reductase expression in the HepG2 cells, and this stimulation was associated with endogenous fructose production and triglyceride accumulation. This stimulatory mechanism was mediated by uric acid-induced oxidative stress and stimulation of the transcription factor nuclear factor of activated T cells 5 (NFAT5). ... These results suggest that uric acid generated during fructose metabolism may act as a positive feedback mechanism that stimulates endogenous fructose production by stimulating aldose reductase in the polyol pathway." (abstract, results, passage verified)

  pubmedfull study (doi)

Obstructive sleep apnea is strongly associated with gout and obesity.

"Obstructive sleep apnea is super associated with gout, it's really associated with obesity." (said at 0:43:24)

Obstructive sleep apnea (OSA) is robustly associated with both gout (and elevated serum uric acid) and obesity. Systematic reviews and meta-analyses show that patients with OSA have a significantly increased risk of developing gout (RR ~1.29) and higher serum uric acid levels, which improve with CPAP therapy. Furthermore, obesity is one of the strongest established risk factors for OSA, with individuals with obesity having nearly a 5-fold higher odds of having OSA compared to normal-weight individuals (OR 4.84).

• supports: The relationship between obesity and obstructive sleep apnea in four community-based cohor… (EClinicalMedicine 2025) · cited 56x in the literature

  "Odds ratios for OSA in subgroups of individuals with overweight and obesity compared to BMI <25 kg/m 2 were 2.18 [1.73-2.76] and 4.84 [3.09-6.00], respectively." (abstract, results)

  pubmedfull study (doi)
• supports: Association between obstructive sleep apnea and gout risk, and the urate-lowering effects … (Sleep medicine 2026)

  "The meta-analysis revealed that (1) OSA patients have higher gout risk (RR = 1.29, 95% CI: 1.11-1.48, p < 0.001); (2) CPAP lowers serum uric acid levels in OSA patients with an effect size approaching moderate magnitude (Hedges's g = -0.49, 95%CI: -0.79 to -0.18)." (abstract, results)

  pubmedfull study (doi)

Obesity is associated with an increased risk for breast cancer, pancreatic cancer, and colon cancer.

"people with obesity have an increased risk for breast cancer and pancreatic cancer and colon cancer." (said at 0:44:48)

A landmark umbrella review of systematic reviews and meta-analyses (Kyrgiou et al., 2017, BMJ) evaluated the evidence across 36 cancer sites and found that adiposity/obesity is supported by strong epidemiological evidence as a risk factor for colon cancer, pancreatic cancer, and postmenopausal breast cancer.

• supports: Adiposity and cancer at major anatomical sites: umbrella review of the literature. (BMJ (Clinical research ed.) 2017) · cited 838x in the literature

  "An increase in body mass index was associated with a higher risk of developing oesophageal adenocarcinoma; colon and rectal cancer in men; biliary tract system and pancreatic cancer; endometrial cancer in premenopausal women; kidney cancer; and multiple myeloma. Weight gain and waist to hip circumference ratio were associated with higher risks of postmenopausal breast cancer in women who have never used hormone replacement therapy and endometrial cancer, respectively." (abstract, results, passage verified)

  pubmedfull study (doi)

In mice lacking functional uricase or with uricase inhibited, cancers metastasize much faster in the presence of high uric acid.

"So we took mice and we knocked out their uricase or we inhibited it in both ways, and when we give them a cancer, it metastasizes much, much faster in the setting of a high uric acid and an absence of uricase." (said at 0:47:20)

The speaker's description matches published experimental findings in rodent models. A 2021 study evaluated breast cancer cell progression in mice with uricase inactivated either genetically (uricase knockout) or pharmacologically (inhibition with oxonic acid), as well as in uricase-transgenic mice. The authors found that loss or inhibition of uricase (which leads to elevated uric acid levels) was associated with a substantial increase in tumor growth and metastases, whereas transgenic uricase expression reduced tumor growth. Because the supporting evidence comes strictly from animal models, the GRADE certainty is very low.

• supports: Brief report: The uricase mutation in humans increases our risk for cancer growth. (Cancer &amp; metabolism 2021) · cited 18x in the literature

  "Experiments were performed in mice in which uricase was inactivated by either knocking out the gene or by inhibiting uricase with oxonic acid. We also studied mice transgenic for uricase. These mice were injected with breast cancer cells and followed for 4 weeks. The inhibition or knockout of uricase was associated with a remarkable increase in tumor growth and metastases." (abstract, methods and results, passage verified)

  pubmedfull study (doi)

In animal experiments, high-salt intake leads to obesity and diabetes through endogenous fructose production, and blocking fructose metabolism prevents this high-salt-induced obesity.

"We put them on salt, you know, there's not much going on for the first two or three months, and then suddenly a little bit later on they start getting fat, and then they get really fat, and they become enormously fat and diabetic. And we can show that it was due to this production of fructose, because if we block their ability to metabolize fructose, even though they're not getting any in their diet, we can block obesity." (said at 0:57:25)

The speaker's claim accurately describes findings published in PNAS (Lanaspa et al., 2018). In mice, high-salt intake triggered endogenous fructose production and metabolism via the aldose reductase–fructokinase pathway, driving hyperphagia, leptin resistance, obesity, and insulin resistance/diabetes. Blocking fructose metabolism (via fructokinase knockout) protected the animals from high-salt-induced obesity. Because this evidence is derived from preclinical animal models, the GRADE certainty is very low for direct application to humans.

• supports: High salt intake causes leptin resistance and obesity in mice by stimulating endogenous fr… (Proceedings of the National Academy of Sciences of the United States of America 2018) · cited 283x in the literature

  "Here we show that high intake of salt activates the aldose reductase-fructokinase pathway in the liver and hypothalamus, leading to endogenous fructose production with the development of leptin resistance and hyperphagia that cause obesity, insulin resistance, and fatty liver." (abstract, results, passage verified)

  pubmedfull study (doi)

Circulating vasopressin, measured via copeptin, is elevated in people with obesity.

"And we actually know that people who are overweight have high vasopressin levels in their blood, and it's the test that's usually measured is called copeptin, but it's a it's like it's a stable measurement of vasopressin and it's high in people with obesity." (said at 0:59:34)

Large population-based observational cohort studies and clinical reviews confirm that copeptin—a stable surrogate marker reflecting circulating arginine vasopressin (AVP) secretion—is significantly elevated in individuals with overweight and obesity, and correlates positively with BMI, waist circumference, and the risk of developing abdominal obesity.

• supports: Plasma copeptin, a unifying factor behind the metabolic syndrome. (The Journal of clinical endocrinology and metabolism 2011) · cited 182x in the literature

  "Copeptin quartile (lowest quartile as reference) was, after adjustment for age, sex, insulin, and diabetes mellitus, associated with hypertension (odds ratios 1.04, 1.07, 1.31; P = 0.004), abdominal obesity (odds ratios 1.21, 1.16, 1.57; P = 0.002), obesity (odds ratios 1.25, 1.15, 1.49; P = 0.01)" (abstract, results, passage verified)

  pubmedfull study (doi)
• supports: Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: th… (International journal of obesity (2005) 2013) · cited 192x in the literature

  "increasing copeptin quartiles predicted incident abdominal obesity (odds ratios 1.55, 1.30 and 1.59; P for trend=0.04)" (abstract, results, passage verified)

  pubmedfull study (doi)
• supports: Oxytocin and Vasopressin Systems in Obesity and Metabolic Health: Mechanisms and Perspecti… (Current obesity reports 2019) · cited 36x in the literature

  "Copeptin, the C-terminal portion of the precursor of arginine-vasopressin, is positively associated with body mass index and risk of type 2 diabetes." (abstract, results, passage verified)

  pubmedfull study (doi)

Dietary consumption of either sugar or salt increases circulating levels of vasopressin in animals.

"and when we were giving sugar to animals as well as salt to animals, we found that vasopressin levels went up in the blood." (said at 0:59:50)

Animal experimental studies demonstrate that oral administration of sugars (fructose, glucose, high-fructose corn syrup) as well as salt increases circulating levels of vasopressin (measured directly or via its surrogate biomarker copeptin) in rodent models. Because the claim specifically describes animal experimental findings, the available pre-clinical literature directly supports the statement.

• supports: Vasopressin mediates fructose-induced metabolic syndrome by activating the V1b receptor. (JCI insight 2021) · cited 55x in the literature

  "Orally administered fructose, glucose, or high-fructose corn syrup increased vasopressin (copeptin) concentrations and was mediated by fructokinase, an enzyme specific for fructose metabolism." (abstract, results, passage verified)

  pubmedfull study (doi)
• supports: Sugar, salt, immunity and the cause of primary hypertension. (Clinical kidney journal 2023) · cited 13x in the literature

  "Leptin levels rise, triggering activation of the sympathetic central nervous system, while vasopressin levels rise, causing vasoconstriction in its own right and stimulating aldosterone production via the vasopressin 1b receptor. Low-grade renal injury and autoimmune-mediated inflammation occur. High-salt diets can amplify this process by raising osmolality and triggering more fructose production." (abstract, results, passage verified)

  pubmedfull study (doi)

Vasopressin acts through the V1b receptor to mediate obesity and the metabolic effects of sugar, and blocking the V1b receptor blocks these effects in animals.

"and it's the vasopressin is blocking or is binding to this V1b receptor, and that is important in how obesity occurs, because when you block that receptor, you can block sugar effects." (said at 1:00:10)

Animal research directly supports the claim that vasopressin promotes sugar (fructose)-induced metabolic syndrome and fat accumulation through the V1b receptor. In murine models, deletion or knocking out of the V1b receptor (V1bR-KO) completely protected mice against fructose-induced metabolic syndrome and obesity, whereas activating this pathway enhanced fructokinase expression. Because the supporting evidence comes strictly from preclinical animal knockout models, the GRADE certainty is very low.

• supports: Vasopressin mediates fructose-induced metabolic syndrome by activating the V1b receptor. (JCI insight 2021) · cited 55x in the literature

  "The vasopressin effects were mediated by the vasopressin 1b receptor (V1bR), as V1bR-KO mice were completely protected, whereas V1a-KO mice paradoxically showed worse metabolic syndrome. The mechanism is likely mediated in part by de novo expression of V1bR in the liver that amplifies fructokinase expression in response to fructose." (abstract, results, passage verified)

  pubmedfull study (doi)